# Desvenlafaxine Succinate (DVS) for Major Depressive Disorder (MDD) in Midlife Men and Women

> **NCT00888862** · PHASE3 · UNKNOWN · sponsor: **Hamilton Health Sciences Corporation** · enrollment: 90 (estimated)

## Conditions studied

- Major Depressive Disorder
- Menopausal Staging and Vasomotor Symptoms (for Females)

## Interventions

- **DRUG:** Desvenlafaxine Succinate

## Key facts

- **NCT ID:** NCT00888862
- **Lead sponsor:** Hamilton Health Sciences Corporation
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-06
- **Primary completion:** 2012-06
- **Final completion:** 2012-10
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2012-02-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00888862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00888862, "Desvenlafaxine Succinate (DVS) for Major Depressive Disorder (MDD) in Midlife Men and Women". Retrieved via AI Analytics 2026-09-14 from https://api.ai-analytics.org/clinical/NCT00888862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*